elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Gefitinib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Gefitinib
RIS
0.001
(Research Intensity Score)
Papers
154
Top papers
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
2019 · 1112 citations
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
2020 · 280 citations
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
2021 · 148 citations
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · 17 citations
Preparation and application of calcium phosphate nanocarriers in drug delivery
2022 · 75 citations
The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene
2020 · 196 citations
Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy
2024 · 16 citations
Hypoxia-Induced Histone Lactylation Drives Cisplatin Resistance in Bladder Cancer by Promoting RBM15-Dependent m 6 A Methylation of IGFBP3
2025 · 12 citations
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
2022 · 58 citations
Newest papers
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study
2026
Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI–treated NSCLC: a cross-database real-world study
2026
Antineoplastic Activity of the Combination Loratadine–Simvastatin–Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies
2026
Afatinib-Induced Acneiform Eruption in EGFR Exon 21 L858R-Mutant Stage IVA Lung Adenosquamous Carcinoma: Dermoscopy-Supported Diagnosis and Complete Resolution Fifteen Days After Drug Withdrawal
2026
Erlotinib-conjugated iridium(III) complexes for EGFR-mediated photodynamic therapy of cancer
2026
NIR-responsive cetuximab-functionalized chitosan–polydopamine hydrogel Co- delivering Ca2+ and gefitinib for EGFR-targeted esophageal cancer therapy via Ca2+- mediated cytotoxicity and potential immunomodulatory effects
2026
Abstract B006: Identification of possible biomarkers for acquired resistance against anti EGFR treatment regimen in a patient derived NSCLC model in vivo
2026
Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB–IV EGFR-mutated NSCLC in China
2026
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · 17 citations
Browse all papers →
Gefitinib's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Gefitinib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link